Biopharmaceutical innovator Dimerix (ASX:DXB) announced plans to conduct a blinded assessment of the statistical assumptions underpinning its ongoing ACTION3 study.
The proactive measure is designed to ensure the trial remains robustly powered to meet its primary clinical endpoints amidst a rapidly shifting landscape for Focal Segmental Glomerulosclerosis treatments.
The decision reflects a disciplined approach to clinical development, with the company prioritising the integrity of its data as it navigates the final stages of the study.
Dr Nina Webster, CEO and Managing Director of Dimerix, emphasised that the review is a vital step in maintaining the program's alignment with current medical standards.
"With the FSGS landscape having evolved since the initiation of the ACTION3 study, we are focused on ensuring the program remains appropriately powered to meet its primary endpoint," Webster stated.
A central component of the review involves the continued emphasis on proteinuria (the presence of abnormal quantities of protein in the urine) as a primary measure.
By focusing on this biomarker, Dimerix aims to strengthen the probability of a successful outcome for the trial.
The company maintains that this clear and disciplined pathway is essential for delivering long-term value to both the patient community and its shareholders.
At the time of reporting, Dimerix’s share price was $0.36.